Neurosense Competitors
| NRSN Stock | USD 1.01 0.01 0.98% |
Neurosense Therapeutics vs TAO Synergies Correlation
Very weak diversification
The correlation between Neurosense Therapeutics and TAOX is 0.54 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Neurosense Therapeutics and TAOX in the same portfolio, assuming nothing else is changed.
Moving against Neurosense Stock
| 0.58 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.39 | KYTX | Kyverna Therapeutics | PairCorr |
| 0.37 | LRMR | Larimar Therapeutics | PairCorr |
| 0.36 | ENGN | enGene Holdings Common | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Neurosense Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Neurosense Therapeutics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Neurosense Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Neurosense and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Neurosense Therapeutics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Neurosense Stock performing well and Neurosense Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Neurosense Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| NRXS | 3.75 | 0.94 | 0.20 | 0.87 | 3.85 | 7.88 | 38.80 | |||
| KLTO | 4.68 | (1.20) | 0.00 | (0.26) | 0.00 | 10.34 | 29.02 | |||
| CLGN | 4.98 | (1.36) | 0.00 | (0.65) | 0.00 | 8.61 | 77.60 | |||
| XCUR | 6.03 | 0.68 | 0.05 | (0.35) | 8.47 | 21.22 | 63.80 | |||
| CVKD | 4.74 | (1.10) | 0.00 | (0.44) | 0.00 | 8.11 | 58.15 | |||
| ENLV | 4.00 | 0.25 | 0.05 | 0.35 | 4.38 | 8.57 | 24.21 | |||
| SONN | 10.16 | 0.00 | 0.00 | 0.08 | 0.00 | 19.48 | 69.59 | |||
| NERV | 4.41 | 0.81 | 0.15 | 0.65 | 4.59 | 12.31 | 25.06 | |||
| RLYB | 2.93 | (0.12) | (0.02) | 0.00 | 3.44 | 6.57 | 19.36 | |||
| TAOX | 5.52 | (1.23) | 0.00 | (0.23) | 0.00 | 11.74 | 33.82 |
Cross Equities Net Income Analysis
Compare Neurosense Therapeutics and related stocks such as Neuraxis, Klotho Neurosciences, and Collplant Biotechnologies Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NRXS | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3 M) | (4.8 M) | (14.6 M) | (8.2 M) | (7.4 M) | (7.8 M) |
| KLTO | (913) | (913) | (913) | (913) | (913) | (913) | (913) | (913) | (913) | (913) | (913) | (1.1 M) | (598.6 K) | (707.5 K) | (6.2 M) | (5.5 M) | (5.3 M) |
| CLGN | (4.5 M) | (4.5 M) | (4.5 M) | (4.6 M) | (3.6 M) | (4.8 M) | (7.3 M) | (5.8 M) | (6.2 M) | (11.2 M) | (5.8 M) | 237 K | (16.9 M) | (7 M) | (16.6 M) | (14.9 M) | (14.2 M) |
| XCUR | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (16.9 M) | (11 M) | (22.4 M) | (26.3 M) | (24.7 M) | (64.1 M) | (2.6 M) | (16.9 M) | (9.7 M) | (8.7 M) | (9.2 M) |
| CVKD | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (8.4 M) | (10.7 M) | (9.6 M) | (10.1 M) |
| ENLV | (229 K) | (229 K) | (229 K) | (1.1 M) | (7 M) | (15.4 M) | (16 M) | (5.9 M) | (4.9 M) | (9.4 M) | (11.8 M) | (14.5 M) | (31.1 M) | (29.1 M) | (15 M) | (13.5 M) | (14.2 M) |
| NERV | (1.1 M) | (1.1 M) | (1.6 M) | (3.3 M) | (56.9 M) | (27.1 M) | (31 M) | (31.5 M) | (50.2 M) | (72.2 M) | 1.9 M | (49.9 M) | (32.1 M) | (30 M) | 1.4 M | 1.3 M | 1.4 M |
| RLYB | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (26.4 M) | (47 M) | (66.7 M) | (74.6 M) | (57.8 M) | (52 M) | (54.6 M) |
| TAOX | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (5.6 M) | (6 M) | (12.8 M) | (11.5 M) | (12.1 M) |
Neurosense Therapeutics and related stocks such as Neuraxis, Klotho Neurosciences, and Collplant Biotechnologies Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Neurosense Therapeutics financial statement analysis. It represents the amount of money remaining after all of Neurosense Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Neurosense Therapeutics Competitive Analysis
The better you understand Neurosense Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Neurosense Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Neurosense Therapeutics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Neurosense Therapeutics Competition Performance Charts
Five steps to successful analysis of Neurosense Therapeutics Competition
Neurosense Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Neurosense Therapeutics in relation to its competition. Neurosense Therapeutics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Neurosense Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Neurosense Therapeutics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Neurosense Therapeutics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Neurosense Therapeutics position
In addition to having Neurosense Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Size And Style ETFs Thematic Idea Now
Size And Style ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Size And Style ETFs theme has 1429 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Size And Style ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Neurosense Therapeutics Correlation with its peers. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Will Biotechnology sector continue expanding? Could Neurosense diversify its offerings? Factors like these will boost the valuation of Neurosense Therapeutics. Anticipated expansion of Neurosense directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Neurosense Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Neurosense Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Neurosense Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Neurosense Therapeutics' market price to deviate significantly from intrinsic value.
It's important to distinguish between Neurosense Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neurosense Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Neurosense Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.